CLINICAL TRIALS PROFILE FOR DIMENHYDRINATE

505(b)(2) Clinical Trials for DIMENHYDRINATE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	Canadian Association of Emergency Physicians	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC	NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	St. Justine's Hospital	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?

All Clinical Trials for DIMENHYDRINATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	Canadian Association of Emergency Physicians	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	St. Justine's Hospital	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
NCT00791960 ↗	Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting	Completed	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	2008-11-01	The purpose of this study will be to determine whether an intravenous dose of dimenhydrinate (also known as Gravol), given before the induction of spinal anesthesia, will decrease the incidence of intraoperative nausea and vomiting in patients undergoing Cesarean delivery. This medication is commonly given during and after the surgery if required, but it is not known whether a preventative dose will decrease the overall incidence of these side effects.

Clinical Trial Conditions for DIMENHYDRINATE

Condition Name

Condition Name for DIMENHYDRINATE
Intervention	Trials
Postoperative Nausea and Vomiting	7
Postoperative Pain	3
Vomiting	2

Condition MeSH

Condition MeSH for DIMENHYDRINATE
Intervention	Trials
Vomiting	11
Nausea	9
Postoperative Nausea and Vomiting	9

Clinical Trial Locations for DIMENHYDRINATE

Trials by Country

Trials by Country for DIMENHYDRINATE
Location	Trials
Canada	10
Brazil	7
Turkey	2
Thailand	1
Jamaica	1

Clinical Trial Progress for DIMENHYDRINATE

Clinical Trial Phase

Clinical Trial Phase for DIMENHYDRINATE
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	9
Phase 3	3

Clinical Trial Status

Clinical Trial Status for DIMENHYDRINATE
Clinical Trial Phase	Trials
Completed	12
Not yet recruiting	4
RECRUITING	3

Clinical Trial Sponsors for DIMENHYDRINATE

Sponsor Name

Sponsor Name for DIMENHYDRINATE
Sponsor	Trials
Pontificia Universidade Catolica de Sao Paulo	3
University of Sao Paulo General Hospital	1
Ciusss de L'Est de l'Île de Montréal	1

Sponsor Type

Sponsor Type for DIMENHYDRINATE
Sponsor	Trials
Other	24
Industry	3

DIMENHYDRINATE Market Analysis and Financial Projection

Last updated: April 28, 2026

Dimenhydrinate: Clinical Trial Update, Market Analysis, and Projection

What clinical trial activity exists for dimenhydrinate?

Dimenhydrinate is an established, off-patent antihistamine used for nausea and vomiting (including motion sickness). Publicly available clinical evidence is dominated by older trials, small studies, and comparative evaluations rather than current phase 3 programs. Recent “clinical trial update” for the molecule is therefore characterized by ongoing or historical trial listings with no clear, current late-stage registration pathway tied to a specific, sponsor-defined, new chemical entity program.

Clinical trial record pattern (high level)

• Therapeutic area: motion sickness, nausea, vomiting
• Typical trial designs: symptomatic efficacy (nausea/vomiting), tolerability, dose comparisons, onset and duration endpoints
• Study era skew: earlier decades dominate the literature, with modern trials more likely to be supportive, comparative, or registry listings rather than late-stage pivotal studies.
• Regulatory context: the drug is generic and widely available; large contemporary development programs are less common than for new drugs.

Implication for investors and R&D planners

• Near-term value drivers are usually formulation (bioavailability, fast-onset, pediatric dosing forms), delivery (OTC vs prescription positioning), and label maintenance rather than new active ingredient development.

Public trial registries and literature A structured, current phase-by-phase update for dimenhydrinate is not supported by consistent evidence of active, late-stage interventional development in mainstream registries; instead, trial activity is scattered and often historical. The strongest consistent sources for trial identification are ClinicalTrials.gov and the peer-reviewed historical literature indexed there. ClinicalTrials.gov record searches for dimenhydrinate generally show older and sporadic interventional entries rather than a steady stream of phase 3 programs for a novel sponsor pathway. (Source: ClinicalTrials.gov [1].)

---

How large is the dimenhydrinate market and what drives demand?

Dimenhydrinate demand tracks:

1. OTC motion sickness and nausea self-care (seasonality and travel-related peaks)
2. Pediatric and family cold/flu symptom bundles where nausea is a secondary indication
3. Travel, commuting, and cruises market dynamics
4. Generic availability and price competition

Because dimenhydrinate is off-patent, market sizing is typically captured under broader “motion sickness / nausea” OTC segments, often reported as:

• OTC antihistamine cold/nausea products
• Motion sickness products
• Antiemetics (OTC overlapping categories)

Commercial reality

• The active ingredient level faces high price elasticity and competition from other OTC antiemetic and antihistamine options (and from non-drug behavioral measures).
• The most profitable lanes are typically brand loyalty and channel execution plus formulation differentiation rather than clinical innovation.

Market segmentation (practical view for planning)

• By channel: OTC retail pharmacy, mass retail, e-commerce
• By geography: North America and Europe are mature; emerging markets grow with pharmacy expansion and travel growth
• By product form: tablets/capsules and pediatric-friendly liquid/chewable presentations; suppository use exists in some markets historically

---

What is the competitive landscape for dimenhydrinate?

Dimenhydrinate competes within a cluster of older OTC and generic agents, including:

• Other antihistamines used for motion sickness and nausea (e.g., meclizine, dimenhydrinate-adjacent antihistamines)
• Non-antihistamine antiemetic classes in prescription settings (less direct for OTC motion sickness, more direct for severe nausea syndromes)

Competitive dynamics that matter

• Switching costs are low because multiple generics and OTC alternatives exist.
• Safety and tolerability (sedation risk, anticholinergic effects) drives consumer and clinician preference.
• Fast-onset and child-friendly dosing can shift share even among identical actives, if the formulation improves usability.

---

What market projections are realistic for dimenhydrinate?

With an off-patent active ingredient, projections depend less on “drug innovation curves” and more on:

• population growth and travel frequency
• OTC category growth rates
• inflation and generics price compression
• formulation and packaging refresh that sustains unit demand

Projection framework (directional, decision-grade)

• Base case: low-to-mid single digit CAGR in unit volume in mature markets, with flat-to-low revenue CAGR due to generic price competition.
• Upside case: share gains from optimized dosing (fast onset) and pediatric-friendly formats.
• Downside case: substitution into other OTC motion sickness agents and further price pressure.

Because the active ingredient is not tied to a modern, sponsor-funded late-stage pipeline, investors typically value dimenhydrinate as a cash-flow asset or a formulation/label-maintenance opportunity rather than as an R&D-led growth story.

---

Where are the highest-value opportunities: R&D and product strategy

Since dimenhydrinate’s active ingredient pathway is mature, the most actionable R&D themes are:

1. Formulation optimization

   • reduce time to effect
   • improve dose uniformity and pediatric acceptance
   • mitigate sedation perception via messaging and usability design

2. Regulatory and label stewardship

   • maintain or expand indication wording consistent with local regulatory frameworks
   • ensure pediatric dosing compliance and safety labeling

3. Channel and bundle strategy

   • retail placement during travel peaks
   • pharmacy “family nausea” shelf strategy
   • alignment with seasonal OTC promotions

---

Key Takeaways

• Dimenhydrinate clinical activity is mainly historical and scattered in interventional listings, with limited evidence of current late-stage pivotal development. (Source: ClinicalTrials.gov [1].)
• The market is mature and generic-driven, with growth tied to OTC category demand and travel-related utilization rather than new scientific differentiation.
• Projections are best modeled as low-to-mid single digit unit growth with flatter revenue growth due to price compression.
• Value creation focuses on formulation, pediatric usability, and channel execution, not new active ingredient discovery.

---

FAQs

1) Is dimenhydrinate still under active clinical development?

Public interventional activity is present in registries, but the dominant pattern is older or sporadic studies rather than a clearly continuous phase 3-to-approval pipeline. (Source: ClinicalTrials.gov [1].)

2) What indications drive most dimenhydrinate demand?

The largest demand drivers are motion sickness and nausea/vomiting management, typically in OTC contexts. (Source: ClinicalTrials.gov [1].)

3) Does the off-patent status limit upside?

Yes. Off-patent status increases generic competition, which typically constrains revenue growth unless a company differentiates via formulation and commercialization.

4) What is the most practical R&D route for companies today?

Formulation upgrades and label/packaging optimization aimed at faster onset, better pediatric usability, and reduced usability friction.

5) How should market projections be modeled?

Use a unit-volume growth base with price-downward pressure layered in, reflecting OTC generics dynamics and substitution among OTC motion sickness agents.

---

References

[1] ClinicalTrials.gov. (n.d.). Search results for “dimenhydrinate”. https://clinicaltrials.gov/